StockData
Cellectis S.A. logo

Cellectis S.A. (CLLS) stock

CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 20, 2026Score 3/30
$1.06+0.02 (+1.92%)

Close on Nov 17, 2026Market cap $106.36MP/E –Yield –

Cellectis total assets

Total assets on the balance sheet at the end of each period.

Cellectis's total assets was $267.37M at Jun 30, 2026. For fiscal 2025 it was $324.72M, down 15.3% from the year before. Over ten years it grew -1.3% a year on average. The highest annual figure on record is $500.84M in fiscal 2018.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$324.72M-15.3%
FY2024Dec 31, 2024$383.54M+14.7%
FY2023Dec 31, 2023$334.27M+28.0%
FY2022Dec 31, 2022$261.22M-31.6%
FY2021Dec 31, 2021$382.08M-18.6%
FY2020Dec 31, 2020$469.47M+0.4%
FY2019Dec 31, 2019$467.47M-6.7%
FY2018Dec 31, 2018$500.84M+50.5%
FY2017Dec 31, 2017$332.88M+0.4%
FY2016Dec 31, 2016$331.43M-10.7%
FY2015Dec 31, 2015$371.31M+122.2%
FY2014Dec 31, 2014$167.08M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$267.37M-34.3%
Q4 FY2025Dec 31, 2025$324.72M-2.9%
Q2 FY2025Jun 30, 2025$353.97M+68.8%
Q4 FY2024Dec 31, 2024$383.54M+68.5%
Q2 FY2024Jun 30, 2024$407.15M+55.9%
Q4 FY2023Dec 31, 2023$334.27M+4.2%
Q3 FY2023Sep 30, 2023$209.70M-45.1%
Q2 FY2023Jun 30, 2023$227.67M-50.2%
Q4 FY2022Dec 31, 2022$261.22M-44.4%
Q2 FY2022Jun 30, 2022$320.88M-32.1%
Q4 FY2021Dec 31, 2021$382.08M-18.3%
Q2 FY2021Jun 30, 2021$457.57M-8.6%
Q4 FY2020Dec 31, 2020$469.47M+41.0%
Q2 FY2020Jun 30, 2020$472.70M+42.6%
Q4 FY2019Dec 31, 2019$467.47M+25.9%
Q4 FY2018Dec 31, 2018$500.84M+199.8%
Q4 FY2017Dec 31, 2017$332.88M–
Q4 FY2016Dec 31, 2016$331.43M–
Q4 FY2015Dec 31, 2015$371.31M–
Q4 FY2014Dec 31, 2014$167.08M–

More Cellectis figures

See a number that looks wrong?